Turn Biotechnologies
PrivateLast Round
M&A
May 21, 2026
Est. Valuation
$59M
Total Funding Raised
$30.1M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Turn Biotechnologies operates in Healthcare & Life Sciences and is based in Mountain View, California. Its latest recorded funding round was a Series A round in September 2023.
Turn Biotechnologies is a biotechnology company that develops mRNA-based therapies to repair and rejuvenate tissue at the cellular level by reprogramming the epigenome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Turn Biotechnologies Comparables
Compare Turn Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Moonwalk Biosciences | 85% | |
| Shift Bioscience | 84% | |
| Rejuvenation Technologies | 84% |
For institutional investors. Book with your work email.
Turn Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | May 21, 2026 | ||||
| Series A | Sep 6, 2023 | ||||
| Grant | Jul 21, 2022 | ||||
| Seed | Apr 11, 2022 | ||||
| Seed | Apr 28, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Turn Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Khosla Ventures | Seed, Series A |
| Gaingels | Series A |
| VitaDAO | Grant |
| LongeVC | Seed |
| ThreeD Capital | Seed |
| Vitality Healthspan Foundation | Seed |
| Astellas Venture Management | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 21, 2026
Daewoong Pharmaceutical participated in the M&A round.
- Sep 30, 2025
Select assets acquired for $300M, anchored by pharma partnership.
For institutional investors. Book with your work email.
Turn Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Turn Biotechnologies's valuation, stock price, and market status.
Is Turn Biotechnologies a public or private company?
Turn Biotechnologies is a private company.
What is the current stock price of Turn Biotechnologies?
Turn Biotechnologies is a private company, so its shares have no public market price. Caplight tracks Turn Biotechnologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Turn Biotechnologies worth (valuation)?
Turn Biotechnologies's valuation is estimated at $59.0M based on funding round data.
Can I buy Turn Biotechnologies stock?
Turn Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Turn Biotechnologies's last funding round?
Turn Biotechnologies's most recent funding round was M&A on May 21, 2026.
Who are the main investors in Turn Biotechnologies?
Key investors in Turn Biotechnologies include Astellas Venture Management.
Will Turn Biotechnologies IPO soon?
No public IPO plans have been announced for Turn Biotechnologies.
How can I track Turn Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades in Turn Biotechnologies's shares on secondary markets.